What Is the Xeomin FDA Approval Date?
Image Metadata – Title: Xeomin Clinical Vial; Creator: Merz Aesthetics; Description: A clinical vial of Xeomin in a medical setting; License: Royalty-Free.
The Xeomin FDA approval date that most people are looking for is July 30, 2010 – the day the FDA officially licensed incobotulinumtoxinA under BLA Number 125360.
Here’s a quick summary of Xeomin’s key FDA approval milestones:
| Year | Approval |
|---|---|
| July 30, 2010 | Initial FDA approval for cervical dystonia and blepharospasm in adults |
| 2011 | Glabellar lines (frown lines) cosmetic approval |
| 2020 | Pediatric chronic sialorrhea (ages 2+) |
| 2021 | Upper limb spasticity in adults and pediatric patients |
| July 2024 | Expanded upper facial lines (forehead and crow’s feet) |
Since that first approval in 2010, Xeomin has grown into one of the most versatile neurotoxins on the market – now covering both therapeutic and cosmetic indications across adult and pediatric populations.
If you’ve been researching which neurotoxin is right for you, understanding this regulatory history matters. It tells you how well-studied a product is and how confident you can be in its safety profile.
I’m Dr. Thomas Jeneby, an Ivy League-trained, board-certified plastic surgeon based in San Antonio with over two decades of experience performing aesthetic procedures – including neurotoxin treatments like Xeomin. Knowing the full Xeomin FDA approval date timeline is something I consider essential when advising patients, and I’m here to walk you through everything you need to know.
Know your xeomin fda approval date terms:
The Initial Xeomin FDA Approval Date and Regulatory Milestone
When Xeomin first arrived on the U.S. medical scene, it marked a major shift in how healthcare providers approached neurotoxin therapy. The official xeomin fda approval date of July 30, 2010, represents the culmination of years of rigorous clinical research and regulatory review. Developed by Merz Pharmaceuticals, Xeomin (incobotulinumtoxinA) was submitted under Biologics License Application (BLA) 125360.
For those interested in the official regulatory tracking, you can view the historical details on the Xeomin FDA Approval History page or search the official FDA database via the Purple Book Search.
What made this initial approval so significant was not just that a new botulinum toxin product was entering the market, but how it was formulated. Unlike earlier neurotoxins, Xeomin was engineered to be a highly purified, “naked” neurotoxin. Through a proprietary manufacturing process, Merz successfully isolated the active 150 kDa botulinum toxin type A molecule, stripping away unnecessary accessory or complexing proteins. This milestone established Xeomin as the first and only U.S. neuromodulator free from complexing proteins.
The 2010 Approval for Cervical Dystonia and Blepharospasm
The initial green light from the FDA in the summer of 2010 was specifically granted for two therapeutic neurological conditions in adult patients: cervical dystonia and blepharospasm.
- Cervical Dystonia: This is a painful, involuntary contraction of the neck muscles that causes the head to twist or turn to one side. By selectively blocking the release of acetylcholine (the chemical messenger that tells muscles to contract), Xeomin successfully relaxes these overactive neck muscles, offering profound relief to patients.
- Blepharospasm: This condition causes involuntary, spasmodic blinking or closing of the eyelids. For many adult patients, blepharospasm can be severe enough to cause functional blindness. Xeomin injections into the muscles surrounding the eyes help calm these spasms, restoring normal eyelid function.
As documented in the official BioSpace Announcement, this approval made the United States the 20th country worldwide to approve Xeomin, bringing a highly anticipated, protein-free alternative to thousands of patients suffering from these challenging focal dystonias.
Expanded Indications and the Evolution of Xeomin Approvals
Image Metadata – Title: Patient Receiving Facial Injection; Creator: Unsplash Contributor; Description: A patient receiving a cosmetic facial injection in a clinical setting; License: Unsplash License (Royalty-Free).
Following its therapeutic debut, Xeomin underwent a rapid evolution. Regulatory approvals expanded outward from niche neurological disorders into mainstream cosmetic medicine, followed by pediatric applications. This expansion has solidified its reputation as a safe, highly adaptable treatment.
To understand why this clean, purified formulation has captured the attention of both medical and cosmetic injectors, it helps to read our comprehensive overview: What is Xeomin?.
Cosmetic Milestones and the Xeomin FDA Approval Date for Glabellar Lines
In 2011, just one year after its initial therapeutic approval, Xeomin crossed over into the aesthetic realm. The FDA approved Xeomin for the temporary improvement in the appearance of moderate to severe glabellar lines (commonly known as frown lines or “11 lines” between the eyebrows) in adult patients.
When we frown, squint, or concentrate, the muscles between our brows contract, pulling the skin together. Over time, these repeated expressions leave permanent creases. Xeomin works by temporarily relaxing these specific muscles, smoothing out the overlying skin. For patients looking to refresh their appearance without looking “frozen,” this approval was a game-changer. You can read more about how we use this treatment to restore a youthful, rested look in our guide on how to Eliminate Facial Wrinkles.
The cosmetic evolution reached another historic milestone in July 2024. The FDA expanded Xeomin’s label, making it the first and only neuromodulator approved for the simultaneous treatment of three upper facial areas: glabellar lines, horizontal forehead lines, and lateral canthal lines (crow’s feet). This landmark approval allows injectors to treat the entire upper face in a single, cohesive session using a standardized, FDA-approved dosing protocol.
Pediatric Approvals and the Expanded Xeomin FDA Approval Date Timeline
Xeomin’s clinical safety profile is further highlighted by its pediatric approvals. In December 2020, the FDA approved Xeomin for the treatment of chronic sialorrhea (excessive drooling) in pediatric patients aged 2 to 17 years. Sialorrhea is a common and often distressing symptom in pediatric patients dealing with neurological conditions like cerebral palsy or traumatic brain injuries.
According to the official Merz Pediatric Approval announcement, this was a major milestone: Xeomin became the first and only neurotoxin approved in the U.S. for pediatric chronic sialorrhea. The approval was supported by a robust Phase 3 clinical study involving 255 children, which demonstrated significant reductions in saliva production with an excellent safety profile. Remarkably, throughout the 64-week study, not a single pediatric patient developed neutralizing antibodies or clinical resistance to the drug.
In 2021, the FDA further expanded the pediatric timeline by approving Xeomin for the treatment of pediatric upper limb spasticity (excluding spasticity caused by cerebral palsy) in patients aged 2 to 17 years, providing a vital therapeutic option for families managing complex pediatric movement disorders.
Recommended Dosages, Administration, and Safety Guidelines
Image Metadata – Title: Preparing Injection Syringe; Creator: Pexels Contributor; Description: A medical professional preparing an injection syringe in a sterile environment; License: Pexels License (Royalty-Free).
Administering Xeomin safely and effectively requires strict adherence to clinical guidelines, precise reconstitution, and a deep understanding of facial and muscular anatomy. Xeomin is supplied as a sterile, lyophilized powder in single-dose vials containing 50 Units, 100 Units, or 200 Units. Because it contains no preservative or accessory proteins, it must be reconstituted with preservative-free 0.9% Sodium Chloride Injection, USP, prior to use.
Before undergoing any treatment, patients often ask us: is this option as safe as other well-known brands? We break down the safety, purity, and clinical data in our resource Is Xeomin Safe?.
For complete safety information, you can review the official FDA Prescribing Information. To see how these doses translate to clinical practice, check out our comprehensive Xeomin Dosing Guide.
Important Warnings and Precautions
Like all botulinum toxin products, Xeomin carries a Boxed Warning regarding the distant spread of toxin effect. In extremely rare cases, the effects of the botulinum toxin may spread from the area of injection to other parts of the body, causing symptoms consistent with botulism. These symptoms can include:
- Dysphagia (difficulty swallowing)
- Dysarthria (speech difficulties)
- Severe muscle weakness
- Breathing difficulties (which can be life-threatening, especially in patients with pre-existing respiratory conditions)
Other key precautions include monitoring for hypersensitivity reactions (such as rash, pruritus, or anaphylaxis) and taking protective measures to prevent corneal exposure or ulceration when treating blepharospasm.
The table below outlines the recommended FDA-approved dosages and injection sites across Xeomin’s primary indications:
| Indication | Recommended FDA-Approved Dosage | Key Injection Sites & Administration Guidelines | Common Adverse Reactions |
|---|---|---|---|
| Glabellar Lines (Frown Lines) | 20 Units total per session | Divided into 5 equal intramuscular injections of 4 Units each (2 in each corrugator muscle, 1 in the procerus muscle). | Injection site bruising, headache, localized swelling. |
| Upper Facial Lines (Simultaneous) | 64 Units maximum total dose | Glabellar: 20 Units (5 sites); Forehead: 20 Units (5 sites); Crow’s Feet: 24 Units (3 sites per side). Retreatment interval: >= 3 months. | Localized bruising, headache, mild eyelid ptosis (drooping). |
| Chronic Sialorrhea (Adults) | 100 Units total per session | Intraglandular injection: 30 Units per parotid gland and 20 Units per submandibular gland on each side. | Tooth extraction, dry mouth, diarrhea, hypertension. |
| Chronic Sialorrhea (Pediatric, 2+) | Dosage based on body weight | Intraglandular injection guided by ultrasound to ensure precise delivery into parotid and submandibular glands. | Bronchitis, headache, nausea, vomiting. |
| Cervical Dystonia (Adults) | 120 Units initial typical dose | Tailored individually; injected into the affected neck muscles (e.g., sternocleidomastoid, splenius capitis). | Dysphagia (difficulty swallowing), neck pain, muscle weakness. |
| Blepharospasm (Adults) | 50 Units initial (25 Units per eye) | Injected into the lateral and medial orbicularis oculi muscles of the upper lid and the lateral orbicularis oculi of the lower lid. | Eyelid ptosis, dry eye, visual impairment, dry mouth. |
| Upper Limb Spasticity (Adults) | Up to 400 Units cumulative dose | Injected into affected muscle groups of the elbow, wrist, and fingers. Max 400 Units per treatment session. | Seizure, nasopharyngitis, dry mouth, upper respiratory tract infection. |
Frequently Asked Questions about Xeomin FDA Approvals
Navigating the regulatory history and clinical safety of neurotoxins can feel overwhelming. Here are clear, evidence-based answers to the most common questions patients ask about Xeomin.
What is the official initial Xeomin FDA approval date?
The official initial xeomin fda approval date is July 30, 2010. On this date, the FDA approved Xeomin for therapeutic use in adults suffering from cervical dystonia and blepharospasm.
What are the current FDA-approved indications for Xeomin?
As of June 2026, Xeomin is FDA-approved for:
- Chronic Sialorrhea in patients aged 2 years and older.
- Upper Limb Spasticity in adults and pediatric patients aged 2 and older (excluding cerebral palsy).
- Cervical Dystonia in adult patients.
- Blepharospasm in adult patients.
- Upper Facial Lines (Glabellar lines, horizontal forehead lines, and lateral canthal lines) in adult patients.
How does Xeomin differ from other neurotoxins?
The primary difference lies in its purity. Xeomin is manufactured using a proprietary process known as XTRACT Technology, which isolates the active neurotoxin and completely removes complexing (accessory) proteins. Because it contains only the pure 150 kDa neurotoxin, it is often referred to as a “naked neurotoxin.”
This unique formulation offers several clinical benefits:
- Lower Risk of Resistance: The body is less likely to form neutralizing antibodies against a protein-free neurotoxin. This makes Xeomin an excellent choice for patients who feel their results with other neurotoxins are starting to fade.
- Storage Stability: Unlike other neurotoxins that require continuous refrigeration, un-reconstituted Xeomin can be stored safely at room temperature for up to 3 to 4 years.
- No Unit Equivalency: It is critical to note that the potency units of Xeomin are specific to its formulation and cannot be directly converted into or compared with the units of any other botulinum toxin product.
To explore these structural differences in greater detail, read our complete guide on the Difference Between Xeomin and Botox.
Conclusion
From its initial xeomin fda approval date on July 30, 2010, to its status as a premier aesthetic and therapeutic treatment, Xeomin has proven itself to be a highly effective, pure, and reliable option. Whether you are looking to smooth away stubborn frown lines, treat complex muscle spasms, or simply explore a cleaner alternative to traditional neurotoxins, Xeomin’s protein-free formulation offers consistent, natural-looking results.
At Spa Black in San Antonio, Texas, we believe that exceptional results begin with expert care. As a premier medical spa owned and guided by board-certified plastic surgeon Dr. Thomas Jeneby, we specialize in providing highly personalized, medically supervised aesthetic treatments. Our experienced injectors understand the unique nuances of facial anatomy, ensuring that every Xeomin treatment is tailored precisely to your goals.
Ready to experience the benefits of the “naked neurotoxin” for yourself? We invite you to take the next step. Contact us today or visit our Xeomin San Antonio service page to schedule your personalized consultation. Let us help you look and feel your absolute best!